Back to dashboard
CommercialPrior AuthMedium impact

Vyvanse (lisdexamfetamine dimesylate)

Blue Cross & Blue Shield of Mississippi·MS · Psychiatry, Pediatrics, Family Medicine +1 more·Medical Policy
Effective date
Not stated
We identified it
Jun 20, 2026
Days to comply

Summary

BCBS Mississippi updated their Vyvanse (lisdexamfetamine) prior authorization policy, establishing strict criteria for ADHD patients ages 6-18 and binge eating disorder patients ages 18-65. Prior authorization is required for all Vyvanse prescriptions with specific quantity limits and trial requirements for alternative medications.

Action Required

Action needed
Immediately: Billing team must ensure prior authorization is obtained for ALL Vyvanse prescriptions before dispensing. Providers must document either: 1) For ADHD patients (6-18 years): inadequate response to at least two different formulary generic extended-release stimulants OR FDA contraindication to all formulary stimulants, 2) For binge eating disorder patients (18-65 years): detailed clinical criteria including binge frequency, symptoms, BMI 25-45, and previous therapy outcomes. Update encounter forms to remind providers of documentation requirements. Claims will be denied without proper prior authorization.